What are the diagnostic criteria for Acute Generalized Exanthematous Pustulosis (AGEP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Diagnosing Acute Generalized Exanthematous Pustulosis (AGEP) requires a comprehensive approach combining clinical evaluation, laboratory tests, and histopathology, with the most recent and highest quality study suggesting that diagnosis depends on both clinical and histologic criteria 1. The diagnosis begins with recognizing the characteristic widespread, non-follicular sterile pustules on an erythematous base that typically appear rapidly, often within 24-48 hours of exposure to the causative agent. Some key points to consider in the diagnosis of AGEP include:

  • Laboratory findings typically include leukocytosis with neutrophilia, mild eosinophilia, and elevated inflammatory markers such as C-reactive protein.
  • A skin biopsy is crucial for confirmation, showing subcorneal or intraepidermal pustules, spongiosis, papillary dermal edema, perivascular infiltrates with neutrophils and eosinophils, and occasional leukocytoclastic vasculitis.
  • The EuroSCAR scoring system can help differentiate AGEP from other pustular conditions, considering factors like morphology, distribution, course of pustules, history of drug exposure, and histopathology.
  • Identifying and discontinuing the causative medication is essential, with antibiotics (particularly beta-lactams), calcium channel blockers, antimalarials, and terbinafine being common triggers, as reported in recent studies 2. Patch testing may be performed later to confirm the specific causative agent, though this is not necessary for immediate management, and recent experimental data suggest an early role of drug-induced innate immune activation and innate cytokines such as interleukin (IL)-1, IL-36, and IL-17 in the pathogenesis of AGEP 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.